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Key messages
What is already known about this subject?
 ► Studies are starting to recruit participants online and 
through patient organisations, but we do not know 
how representative these groups are.
What does this study add?
 ► Patient organisation members with rheumatoid ar-
thritis (ra) were broadly representative of the gen-
eral ra population, and  online health community 
(OHc) users with ra were younger, more recently 
diagnosed and from more deprived areas.
 ► a high proportion of OHc users were willing to take 
part in all types of research (surveys, use of an app 
or activity tracker, and trials).
How might this impact on clinical practice?
 ► Future studies may be able to recruit more efficient-
ly from OHcs and patient organisations with confi-
dence in how these populations represent the study 
population.
AbstrAct 
Objectives to describe (1) the representativeness of (a) 
users of an online health community ( HealthUnlocked. com 
(HU)) with rheumatoid arthritis (ra) and (b) paid members 
of an ra patient organisation, the national rheumatoid 
arthritis Society (nraS), compared with the general ra 
population; and (2) the willingness of HU users with ra to 
participate in types of research (surveys, use of an app or 
activity tracker, and trials).
Methods a pop-up survey was embedded on HU to 
determine the characteristics of users and their willingness 
to participate in research. an anonymous data set of 
nraS member characteristics was provided by the nraS 
(n=2044). to represent the general ra population, 
characteristics of people with ra were identified from the 
clinical Practice research Datalink (cPrD) (n=20 594). 
cross-sectional comparisons were made across the three 
groups.
Results compared with cPrD, HU respondents 
(n=615) were significantly younger (49% aged below 55 
years compared with 23% of cPrD patients), significantly 
more deprived (21% in the most deprived townsend 
quintile compared with 12% of cPrD patients) and had 
more recent disease, with 62% diagnosed between 
2010 and 2016 compared with 37% of cPrD patients. 
nraS members were more similar to the cPrD, but 
significantly under-represented those aged 75 years 
or over and over-represented those aged 55–75 
years compared with the cPrD. High proportions of HU 
users were willing to participate in future research of all 
types.
Conclusions nraS members were broadly representative 
of the general ra population. HU users were younger, more 
deprived and more recently diagnosed. HU users were 
willing to participate in most types of research.
InTROduCTIOn
Large population studies often require signif-
icant numbers of participants to generate 
enough statistical power. This often requires 
multisite recruitment through rheumatology 
departments. A study of trials conducted 
in 2002–2008 found only 55% recruited to 
their prespecified sample size.1 This leads to 
an underpowered study and possible incon-
clusive results.
Study recruitment may be improved in both 
numbers and efficiency by recruiting patients 
directly. This may be coordinated via patient 
organisations or, as patients are increasingly 
online,2 through the internet. For example, 
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studies have recruited through social media,3 4 recruited 
through online forums,5–7 advertised on health websites4 
or advertised based on health-related search terms on 
Google.8 However the representativeness of online 
health communities (OHCs) and patient organisations, 
particularly in a rheumatoid arthritis (RA) population, 
is not clear.
The aims of this study were to describe (1) the repre-
sentativeness of paid members of a patient organisation 
with prevalent RA and users of an OHC with RA when 
compared with the general RA population, and (2) the 
types of studies that OHC users with RA would participate 
in.
MeTHOds
design
This cross-sectional study compared the characteristics of 
adults with RA from the National Rheumatoid Arthritis 
Society (NRAS) members who had paid for membership 
and visitors to the NRAS community group on  HealthUn-
locked. com (HU) with adults with RA identified from 
the Clinical Practice Research Datalink (CPRD), a data-
base of anonymised UK primary care electronic medical 
records. As the CPRD is broadly representative of the UK 
population,9 adults with RA identified from the CPRD 
were considered representative of adults with RA in the 
UK.
Patient organisation population
The NRAS is a patient organisation for people living with 
RA. When people join NRAS or renew their member-
ship, they can provide demographic and medical infor-
mation. An anonymised data set of all members, past and 
present up until 1 May 2016, was provided by the NRAS. 
For consistency with the other data sets, and to avoid 
selection bias, only current NRAS members were used. 
The data set contained (self-reported) year of RA diag-
nosis, ethnicity, current age, gender, employment status, 
and ever use of disease-modifying antirheumatic drugs 
(DMARDs), biologics and glucocorticoids (GC). To be 
included in the analyses, respondents had to be resi-
dents in the UK to allow comparison with the other UK 
data sets.
Hu population
HU is Europe’s largest OHC, with over 4.5 million visitors 
per month.10 The NRAS has a community group on HU 
for people with RA with, on average, 169 000 visitors per 
month. Anybody can visit the NRAS community on HU 
irrespective of a diagnosis of RA, NRAS membership or 
following the NRAS HU community. As people join HU 
without providing demographic information, a survey 
was developed to determine self-reported RA diagnosis, 
year of RA diagnosis, medications used, willingness to 
participate in different types of research (including ques-
tionnaires of varying durations, using an app, wearing an 
activity tracker and different types of trial), demographics 
(age, gender, employment, postcode and ethnicity) and 
the types of electronic devices owned (details of survey 
development in online supplementary file 1). After 
review by a combined patient and public involvement 
group and agreement with the NRAS, the finalised 
survey (online supplementary figure 1) was embedded 
in all posts within the NRAS HU community and popped 
up for completion when these posts were viewed by 
someone with a UK IP address. Prior to starting the 
survey, respondents confirmed they were over 18 years of 
age. The survey then started with an eligibility question 
to determine self-reported RA. The survey started on 6 
May 2016 and was live for 3 months or until 1000 people 
had completed the survey, whichever was soonest. Post-
code was converted to Townsend Deprivation Index11 by 
a health data scientist outside of the research team prior 
to analysis.
CPRd population
A prevalent cohort of patients with a diagnosis of RA 
prior to 1 June 2016 was identified using a validated 
algorithm.12 Eligibility criteria were (1) aged 18 years or 
over at RA diagnosis, (2) registered at a practice on 1 
May 2016 and (3) data met the CPRD quality standards.9 
Age, gender, year of RA diagnosis, ethnicity, ever DMARD 
and GC use, and Townsend Deprivation Index (for prac-
tices that consented to linkage) were identified for these 
patients (covariate definitions in online supplementary 
file 1).
Analysis
For each data set, the characteristics were categorised 
and tabulated to match the HU survey responses to allow 
comparison between data sets. A Z-test for the difference 
in proportions within each category of each character-
istic was calculated comparing NRAS with CPRD, and 
HU with CPRD, where CPRD data were available. The 
characteristics of those who would definitely or probably 
take part in each type of research are reported. Logistic 
regression was used to identify any characteristics that 
were independently associated with definite or probable 
participation in each type of research.
Missing data
To be included in this analysis, individuals had to have 
information on at least age and gender. For CPRD employ-
ment status was available for less than 5% of patients so 
it was not used in this analysis. For NRAS members, post-
code and therefore Townsend Deprivation Index were 
unavailable. For all variables, except age and gender, 
when the variable was available for the data set, the 
percentage of missing data is reported.
ResulTs
data sets
nraS
The NRAS provided a data set of 4505 current and past 
members. Of those, 1498 were not currently members, 
22 were from overseas and 941 did not have information 
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on age and gender, resulting in a data set of 2044 current 
members with RA.
HealthUnlocked survey
The HU survey was live for 74 days between 6 May 2016 
and 12 August 2016 and had 100 112 pop-ups to unique IP 
addresses. There were 2647 pop-ups clicked, 900 respond-
ents agreed to take part, 750 respondents were eligible, 
and 135 did not provide age and gender, resulting in 
615 respondents available for analysis. Recruitment was 
steady with an average of 12 responses per day.
cPrD
Of 4 776 441 people in the CPRD, there were 20 594 
(0.43%) patients with a diagnosis of RA on 1 June 2016.
Characteristics
Table 1 and figure 1 show that NRAS members had a 
reasonably similar age distribution to patients with RA 
from the CPRD up to age 55. After this age there were 
statistically significant differences in proportions, with 
an over-representation of people aged 55–75 years and 
an under-representation of people aged 75 years and 
over in NRAS members. HU users were a significantly 
younger population compared with the CPRD, with 
fewer responders aged 65 years or over. Both NRAS and 
HU were predominantly female, with significantly higher 
proportions (~85%) compared with CPRD (70%). HU 
users had shorter disease duration, with significantly 
more respondents diagnosed between 2010 and 2016 
(62%) compared with CPRD participants (37%), while 
NRAS members has a longer disease duration, with 
significantly fewer people diagnosed between 2010 and 
2016 (25%). HU responders had a significantly higher 
proportion of people from more deprived areas (most 
deprived Townsend quintile: HU: 22% vs CPRD 12%) 
and significantly less from affluent areas (least deprived 
Townsend quintile: HU: 18% vs CPRD 23%) (data not 
available for NRAS members). All DMARDs had signifi-
cantly more ever use in both HU and NRAS compared 
with CPRD.
 
Participation in future research (Healthunlocked only)
HU responders commonly reported they were defi-
nitely or probably willing to take part in future research, 
particularly questionnaires, with 89% reporting willing-
ness to complete a questionnaire of 10 min. A lower 
proportion reported willingness to use an app (63%) 
compared with wearing an activity tracker (74%). Half 
of the respondents reported willingness to take part in a 
drug trial via the internet or with site visits. When strati-
fied by age, overall those over 65 years of age reported less 
willingness to take part in all research types. When strati-
fied by gender, men reported more willingness to use an 
app while women reported more willingness to wear an 
activity tracker (table 2). The most striking result from 
multivariate logistic regression showed that participants 
over 45 years of age were significantly less willing to use 
an app compared with those aged 18–34 years. Those 
aged 45–54 years had a 92% lower odds of using an app 
(OR: 0.08 (95% CI 0.01 to 0.58)), and those aged 75 years 
and over had 98% lower odds of using an app compared 
with those aged 18–34 years (OR: 0.02 (95% CI 0.002 to 
0.23)). There were no statistically significant differences 
by gender (online supplementary table 1).
dIsCussIOn
This study shows that people with RA who 
were NRAS members were reasonably representative of 
the general RA population, although fewer were aged 75 
years or over. HU visitors were a younger RA population, 
with more recent disease and more deprivation than the 
general RA population. Most respondents from the OHC 
were willing to take part in studies with lower burden. 
More than half were willing to take part in any type of 
study including a drug trial via the internet. Younger 
participants were more willing to use an app. We have 
also demonstrated that over 600 responses to a short 
questionnaire can be collected over a short period of 
time using pop-ups within an OHC.
Recruiting online through HU was a straightforward 
and less labour-intensive method of recruiting a reason-
ably large sample of respondents in a short space of time. 
Once the survey had been designed and then imple-
mented by HU, other than monitoring the numbers of 
surveys completed, it did not require further work by 
the study team as data were automatically captured. This 
contrasts to more traditional methods where a person 
is required to collect data for each survey throughout 
data collection. Ninety per cent of those aged 55–64 
reported they recently used the internet in a UK national 
survey.13 This is seen in this study with good represen-
tation of people aged 45–65 years in our sample. Those 
aged over 75 years were not well represented and may be 
expected given that one in four of those aged 75 or over 
are online,13 and this may impact the generalisability of 
study results and would need to be considered by inves-
tigators designing studies. For example, if the disease of 
interest affects elderly people, studies using HU may wish 
to consider additional recruitment sources to ensure that 
elderly patients are represented. Conversely, if investi-
gators are interested in deprivation or people recently 
diagnosed with RA, then HU may be a good source of 
participants.
Few studies have looked specifically at the representa-
tiveness of members of a patient organisation or internet 
users with RA. A study including a group of patients 
with RA found that internet users were younger, more 
educated and more commonly employed compared with 
those who did not use the internet for health.14 In this 
study HU responders were younger, with a similar propor-
tion employed compared with NRAS members, although 
we did not have CPRD as comparison. Although there 
was no CPRD comparison, the proportion who had ever 
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Table 1  Characteristics of patients with RA who are NRAS members, or who responded to a survey on HU and those 
identified from CPRD
CPRD  
(N=20 594)
NRAS 
(N=2044)
Difference in 
proportion compared 
with CPRD (95% CI) P values 
HU
(N=615)
Difference in 
proportion compared 
with CPRD (95% CI) P values n (%) n (%) n (%)
Age (years) 
  18–34 499 (2.4) 37 (1.8) 0.6 (−0.002 to 1.2) 0.08 26 (4.2) −1.8 (−3.4 to −0.02) 0.005
  35–44 1249 (6.1) 129 (6.3) −0.2 (−1.3 to 0.9) 0.66 79 (12.9) −6.8 (−9.4 to −4.1) <0.001
  45–54 2936 (14.3) 311 (15.2) −1 (−3 to 0.7) 0.24 195 (31.7) −17.5 (−21.2 to −13.7) <0.001
  55–64 4484 (21.8) 568 (27.8) −6 (−8 to −4) <0.001 218 (35.5) −13.7 (−17.5 to −9.9) <0.001
  65–74 5643 (27.4) 709 (34.7) −7 (−9 to −5) <0.001 81 (13.2) 14.2 (11.5 to 17.0) <0.001
  75 and over 5783 (28) 290 (14.2) 13.9 (12.3 to 15.5) <0.001 16 (2.6) 25.4 (24.1 to 26.9) <0.001
Gender 
  Female 14 440 (70.1) 1728 (84.5) −0.18 (−0.21 to −0.16) <0.001 544 (88.5) −18.3 (−20.9 to −15.7) <0.001
Year of RA diagnosis 
  <1990 34 (0.2) 274 (14.5) −14.3 (−15.9 to −12.7) <0.001 39 (6.3) −6.2 (−8.1 to −4.2) <0.001
  1990–1994 869 (4.2) 122 (6.5) −2.2 (−3.4 to −1.1) <0.001 22 (3.6) 0.6 (−0.9 to 2.1) 0.43
  1995–1999 1756 (8.5) 178 (9.4) −0.9 (−2.3 to 0.5) 0.19 32 (5.2) 3.3 (1.5 to 5.1) 0.004
  2000–2004 4336 (21.1) 304 (16.1) 5.0 (3.2 to 6.7) <0.001 46 (7.5) 13.5 (11.4 to 15.7) <0.001
  2005–2009 5962 (29) 540 (28.6) 0.4 (−1.7 to 2.5) 0.72 95 (15.5) 13.5 (10.6 to 16.4) <0.001
  2010–2016 7637 (37.1) 473 (25) 12.1 (10 to 14.1) <0.001 381 (62) −24.9 (−28.8 to −21.0) <0.001
  Missing 0 153 0
Employment status 
  Full-time employed 543 (24.1) 387 (23.6)
  Part-time employed 418 (18.5) 288 (17.5)
  Unemployed 304 (13.5) 280 (17)
  Retired 698 (30.9) 577 (35.1)
  Retired due to 
arthritis
151 (6.7) 83 (5.1)
  Not working due to 
ill health
142 (6.3) 28 (1.7)
  Missing NA 401 0
Ethnicity 
  White 8931 (93.9) 1572 (98.4) −4.5 (−5.3 to −3.7) <0.001 578 (94.6) −0.73 (−2.6 to 1.1) 0.47
  Mixed 44 (0.5) 5 (0.3) 0.1 (−0.2 to 0.5) 0.40 8 (1.3) −0.8 (−1.8 to 0.06) 0.005
  Asian 315 (3.3) 12 (0.8) 2.6 (2.0 to 3.1) <0.001 11 (1.8) 1.5 (0.3 to 2.6) 0.04
  Black 147 (1.6) 5 (0.3) 1.2 (0.9 to 1.6) <0.001 13 (2.1) −0.58 (−1.8 to 0.6) 0.26
  Other 77 (0.8) 4 (0.3) 0.6 (0.3 to 0.9) 0.02 1 (0.2) 0.6 (0.3 to 1.0) 0.08
  Missing 11 080 446 2
Townsend Deprivation  
Index 
  1 (least deprived) 2807 (23.1) 103 (18.3) 4.9 (1.6 to 8.1) 0.007
  2 2949 (24.3) 112 (19.9) 4.4 (1 to 7.8) 0.016
  3 2543 (20.9) 107 (19) 2.0 (−1.3 to 5.3) 0.26
  4 2329 (19.2) 119 (21.1) −1.9 (−5.4 to 1.5) 0.26
  5 (most deprived) 1514 (12.5) 123 (21.8) −9.3 (−12.8 to -5.9) <0.001
  Missing 8452 NA 49
Ever taken methotrexate 
  Yes 14 553 (70.7) 1783 (87.2) −16.6 (−18.1 to −15.0) <0.001 511 (84.9) −14.2 (−17.1 to −11.3) <0.001
  Missing or  
unknown
0 0 13
Continued
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CPRD  
(N=20 594)
NRAS 
(N=2044)
Difference in 
proportion compared 
with CPRD (95% CI) P values 
HU
(N=615)
Difference in 
proportion compared 
with CPRD (95% CI) P values n (%) n (%) n (%)
Ever taken sulfasalazine 
  Yes 9742 (47.3) 1064 (52.1) −4.7 (−7 to −2.5) <0.001 339 (56.9) −9.6 (−13.6 to −5.5) <0.001
  Missing or unknown 0 0 19
Ever taken hydroxychloroquine 
  Yes 8255 (40.1) 883 (43.2) −3.1 (−5.4 to −0.9) 0.006 359 (60.1) −20 (−24 to −16) <0.001
  Missing or unknown 0 0 18
Ever taken leflunomide 
  Yes 2576 (12.5) 378 (18.5) −6 (−7.7 to −4.2) <0.001 113 (19) −6.5 (−9.7 to −3.3) <0.001
  Missing or unknown 0 0 21
Ever taken DMARDs* 
  Yes 18 683 (90.7) 1956 (95.7) −5 (−6 to −4) <0.001 537 (93.4) −2.7 (−4.7 to −0.6) 0.029
  Missing or unknown 0 0 106
Ever taken glucocorticoids 
  Yes 11 889 (57.7) 351 (17.2) 40.6 (38.8 to 42.3) <0.001 368 (61.7) −4 (−8 to −0.05) 0.05
  Missing or unknown 0 0 19
Ever taken biologics 
  Yes 897 (43.9) 196 (32.9)
  Missing or unknown 20 594 0 20
*Ever taken DMARDs is based on the ever taken methotrexate, ever taken sulfasalazine, ever taken hydroxychloroquine and ever taken leflunomide 
data.
CPRD,  Clinical PracticeResearch Datalink; DMARD, disease-modifyingantirheumatic drug; HU,  HealthUnlocked.com; NA, not available; NRAS,  
National RheumatoidArthritis Society; RA,  rheumatoid arthritis. 
Table 1  Continued
Figure 1  Proportions in each age group by 
data set. CPRD, Clinical PracticeResearch Datalink; HU,  
HealthUnlocked.com; NRAS, National RheumatoidArthritis 
Society.
taken biologics was high in both HU and NRAS compared 
with the reported UK estimates of 11%–16%.15 16 This 
may indicate that both NRAS and HU respondents have 
more severe disease requiring biologics, and this may be 
why they are using HU or NRAS. However as we do not 
have disease activity measures, we cannot be sure of this.
There were some limitations to this study. RA diagnosis 
in the CPRD relies on Read (diagnosis) codes and drug 
codes so there may be some misclassification. The preva-
lence rate of RA (0.43%) is lower than the 1% prevalence 
otherwise estimated,17 which supports some misclassifica-
tion. RA diagnosis relied on self-report for both the NRAS 
and HU, so there may have been some misclassification; 
however, as these groups are both specific for RA, it is likely 
that any misclassification would be small. NRAS charac-
teristics relied on members providing personal details: 
there may be some selection bias if those who gave infor-
mation were different from those who did not. Further to 
this, as NRAS membership requires payment, there may 
be some selection bias in that NRAS members may be 
less deprived than the general population; however, we 
were unable to capture the Townsend Deprivation Index 
for this group. There may be some HU respondents 
who were NRAS members also; 114 HU respondents 
indicated they were NRAS members. However, it was not 
possible to cross-reference the NRAS and HU data sets. 
The HU characteristics reflect the characteristics of those 
who completed the survey, so may not be representative 
of all HU users, but does provide insight into the char-
acteristics of those willing to join studies via this route. 
Although we did not survey NRAS paid members about 
their willingness to participate in research, recent experi-
ence demonstrates that patients with RA, both members 
and non-members, are responsive to participating in 
research following outreach from the NRAS.
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Table 2  Proportion of HealthUnlocked users who would definitely or probably take part in types of research
  Characteristics
Type of research
Complete questionnaires Participate in trials
Single 10 min
Multiple 
questionnaires over 
months? Using an app
Wearing 
an activity 
tracker
Non-drug 
treatment
Drug 
treatment 
via internet 
alone
Drug 
treatment 
with site 
visits
Total 546 (89.1) 503 (82.1) 387 (63.1) 453 (73.9) 401 (65.4) 305 (49.8) 327 (53.3)
Age category (years) 
  18–34 23 (88.5) 19 (73.1) 25 (96.2) 20 (76.9) 18 (69.2) 12 (46.2) 15 (57.7)
  35–44 73 (92.4) 69 (87.3) 60 (76) 65 (82.3) 55 (69.6) 48 (60.8) 51 (64.6)
  45–54 172 (88.2) 155 (79.5) 123 (63.1) 145 (74.4) 134 (68.7) 108 (55.4) 108 (55.4)
  55–64 201 (92.2) 184 (84.4) 133 (61) 157 (72) 138 (63.3) 100 (45.9) 111 (50.9)
  65–74 63 (77.8) 65 (80.3) 41 (50.6) 58 (71.6) 48 (59.3) 32 (39.5) 38 (46.9)
  75  and over 16 (100) 13 (81.3) 6 (37.5) 9 (56.3) 9 (56.3) 5 (31.3) 5 (31.3)
Gender 
  Female 483 (89.1) 446 (82.3) 337 (62.2) 408 (75.3) 353 (65.1) 267 (49.3) 288 (53.1)
Employment status 
  Full-time 
employment
140 (89.7) 122 (78.2) 102 (65.4) 119 (76.3) 105 (67.3) 78 (50) 72 (46.2)
  Part-time 
employment
115 (88.5) 102 (78.5) 75 (57.7) 90 (69.2) 78 (60) 64 (49.2) 71 (54.6)
  Unemployed 21 (87.5) 20 (83.3) 16 (66.7) 18 (75) 16 (66.7) 12 (50) 16 (66.7)
  Retired 101 (83.5) 98 (81) 67 (55.4) 84 (69.4) 69 (57) 47 (38.8) 53 (43.8)
  Retired due to 
arthritis
59 (86.8) 59 (86.8) 44 (64.7) 50 (73.5) 43 (63.2) 34 (50) 40 (58.8)
  Not working due 
to ill health
110 (96.5) 102 (89.5) 83 (72.8) 92 (80.7) 90 (79) 70 (61.4) 75 (65.8)
  Missing 2 2 2 2 2 2 2
Ethnicity 
  White 518 (89.6) 481 (83.2) 362 (62.6) 426 (73.7) 373 (64.5) 291 (50.4) 311 (53.8)
  Mixed 8 (100) 7 (87.5) 6 (75) 7 (87.5) 6 (75) 5 (62.5) 5 (62.5)
  Asian 7 (63.6) 3 (27.3) 6 (54.6) 7 (63.6) 7 (63.6) 3 (27.3) 3 (27.3)
  Black 10 (76.9) 9 (69.2) 10 (76.9) 11 (84.6) 13 (100) 5 (38.5) 6 (46.2)
  Other 1 (100) 1 (100) 1 (100) 1 (100) 0 (0) 1 (100) 1 (100)
  Missing 4 4 4 4 4 4 4
Townsend Deprivation Index 
  1 96 (93.2) 86 (83.5) 60 (58.3) 73 (70.9) 58 (56.3) 52 (50.5) 50 (48.5)
  2 103 (92) 96 (85.7) 72 (64.3) 92 (82.1) 84 (75) 58 (51.8) 58 (51.8)
  3 100 (93.5) 86 (80.4) 71 (66.4) 84 (78.5) 78 (72.9) 64 (59.8) 66 (61.7)
  4 107 (89.9) 102 (85.7) 73 (61.3) 77 (64.7) 68 (57.1) 54 (45.4) 63 (52.9)
  5 104 (84.6) 101 (82.1) 87 (70.7) 97 (78.9) 91 (74) 59 (48) 71 (57.7)
  Missing 51 51 51 51 51 51 51
This study gives an indication of the representativeness 
of groups that investigators may consider using to recruit 
people with RA to studies, while also demonstrating the 
feasibility of recruitment from OHCs. People in OHCs 
are willing to take part in many types of research, with 
the proportion declining as the burden of the research 
increases.
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